Korea’s Samsung And Biogen Idec Initiate JV For Global Biosimilars Development
This article was originally published in PharmAsia News
The $300 million Korean joint venture gives Samsung a global stage but raises questions about its Rituxan biosimilars program.
You may also be interested in...
SEOUL - Samsung Biologics, which hopes to establish itself as a global contract manufacturer in a long journey to become a global biopharmaceutical company, said it will eventually try to sell its biosimilars in the U.S. and EU markets rather than emerging markets
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
SEOUL - South Korea's leading conglomerate Samsung Group is following in the footsteps of Korea's biosimilar front-runner Celltrion in beginning its biopharmaceutical journey as a contract manufacturing organization via a joint venture announced Jan. 25 with multinational contract research organization Quintiles Transnational Corp.
Nichi-Iko Takes Share Of Korean Biosimilar Firm, Gains Japanese Rights For Remicade And Herceptin Generics
TOKYO - Nichi-Iko has upped its capability to bring biosimilars to the Japanese market, buying a 33 percent stake in South Korean biosimilar firm Aprogen, giving the Japanese generics maker exclusive rights to Aprogen products in Japan